Exco InTouch Joins Critical Path Institute ePRO Consortium To Advance Electronic Data Capture In Clinical Trials

Exco InTouch, the leading provider of patient engagement, data collection and communication solutions for the pharmaceutical and healthcare sectors, recently announced that it has joined the Electronic Patient-Reported Outcome (ePRO) Consortium, a programme run by the Critical Path Institute (C-Path), which strives to enhance the quality of patient reported outcomes (PRO) in the evaluation of new pharmaceuticals.

The ePRO Consortium is committed to improving the quality, practicality and acceptability of electronic data capture (EDC) methods used in clinical trials for PRO endpoint assessment. As PRO endpoints have become increasingly common in studies for evaluating patients’ perspectives of a particular drug, the requirement for better measures of patients’ experiences has become even more critical. Exco InTouch will work closely with other Consortium members from a number of industry-leading providers of innovative electronic data collection technologies, to develop guidelines for the adaptation of PRO measures to the appropriate ePRO solutions.

The ePRO Consortium will generate measurement equivalence data, develop specification documents and data standards, and produce methodological guidance on measurement issues related to ePRO applications. The association will also work closely with C-Path’s PRO Consortium, a group of 25 pharmaceutical companies working to develop novel PRO measures, with the goal of making these new measures available for electronic data capture formats. The aim of the programme is to enhance public health by optimising the value of PRO data in medical product evaluation and clinical decision making.

“Exco InTouch is delighted to join the ePRO Consortium to help advance the science of electronic data capture and create standardised guidelines to ensure all data collated electronically in clinical trials is valid and reliable,” comments Tim Davis, CEO of Exco InTouch. “The Consortium provides a neutral and collaborative environment for the industry to work together to develop and advocate consistent approaches for drug development.”

About Critical Path Institute (C-Path)
C-Path is an independent non-profit institute created in 2005 by the University of Arizona and the U.S. Food and Drug Administration (FDA). Its neutral status allows C-Path to serve as an effective facilitator among scientists from the government, academia and the private sectors. C-Path has forged key partnerships, created collaborations and helped build new working relationships among federal regulators and the pharmaceutical industry. Led by C-Path, scientists from academia, biotechnology companies, the government and pharmaceutical industry are working together to develop innovative new testing methods that enable life-saving drugs, devices and biological products to reach patients faster and with greater safety.

About Exco InTouch
Exco InTouch is the trusted global innovator of regulatory compliant, mobile and digital patient engagement solutions for life sciences and healthcare companies involved in clinical, late phase and mHealth research. Using a combination of patented software and services delivered in a cloud environment, Exco’s solutions can be utilised on any electronic device. This safe, secure platform facilitates compliant patient communication across the clinical development process from early phase development right through to long term studies and mHealth. As a result, Exco can help its customers to improve clinical outcomes by putting the patient at the heart of a study and enhancing the overall patient experience.

Exco’s solutions are currently being used by hundreds of thousands of patients in over seventy countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.